MedTrace Logo

Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

NCT06201819 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-01-18

No results posted yet for this study

Summary

Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.

Conditions

  • Weight Loss
  • Bariatric Surgery Candidate
  • Obesity, Morbid

Interventions

DRUG

Liraglutide injection

Liraglutide (GLP-1 analog) injection during 3 months

Sponsors & Collaborators

  • Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-18
Primary Completion
2023-03-18
Completion
2023-05-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201819 on ClinicalTrials.gov